Senior Manager, Corporate Communications
JANESVILLE, Wis., Aug. 6, 2021 – SHINE Medical Technologies LLC today announced the completion of its new corporate headquarters. The company now has three facilities on its campus on U.S. Highway 51 across from the Southern Wisconsin Regional Airport. SHINE expects to complete a fourth facility, its large-scale therapeutics production facility, next year.
“SHINE has always been proud to have our headquarters located in Janesville,” said Greg Piefer, Founder and CEO of SHINE. “The completion of our new headquarters near our isotope production hub has been long planned and supports our work to become the leader in medical isotope production technology while remaining rooted as part of the Janesville economy.
“Our new headquarters enables our Janesville employees to work together again, after being spread through multiple locations prior to and during COVID. Our new space was designed to maximize communication, creativity and production as we begin to bring our isotope facilities online and look to expand our target markets in the future.
“This new facility also is a continuation of the outstanding partnership we have with the City of Janesville, the private sector and the community,” Piefer said. “We are grateful to the city, T5 Real Estate Solutions and J.H. Findorff & Son for their collaboration on this project. We look forward to continuing to be an active member of the community.”
The new headquarters occupies 35,000-square-feet, including ample work and meeting space for approximately 200 employees in addition to fitness and other amenities.
“SHINE continues to be a great partner with the City of Janesville and our community,” said Gale Price, Economic Development Director, City of Janesville. “SHINE now has three facilities on its campus and we believe will become the center of medical isotope production. We look forward to continuing to partner with SHINE. It’s innovation, perseverance and ingenuity are changing the face of Janesville.”
About SHINE Medical Technologies
SHINE is a nuclear technology company committed to improving the lives of people and the planet. The company is focusing its fusion-based technology initially on advanced industrial imaging and the production of diagnostic and therapeutic isotopes. These isotopes include molybdenum-99, a diagnostic isotope used to diagnose heart disease, cancer, and other conditions, and lutetium-177, a therapeutic isotope that holds the promise of significantly improving the outcome of some cancer patients. SHINE has a long-term strategy to solve some of humanity’s biggest problems, including nuclear waste recycling and the production of clean fusion energy, in addition to advanced industrial imaging and medical isotopes, by pursuing our vision for progressively broad and impactful uses of fusion technology. For more information about SHINE, please visit our website at www.shinemed.com.